Patents Assigned to Mylan Specialty L.P.
-
Publication number: 20230172943Abstract: Oral solid pharmaceutical compositions containing meloxicam co-crystals described herein allow for the use of meloxicam for the treatment of acute pain. In particular, the improved dissolution and bioavailability of the meloxicam co-crystal compositions provide more rapid uptake of meloxicam in vivo as evidenced by increase blood plasma concentrations in a decreased amount of time following administration. A correlation between improved plasma concentrations and in vivo analgesic action are provided for the first time.Type: ApplicationFiled: April 20, 2021Publication date: June 8, 2023Applicant: Mylan Specialty L.P.Inventors: Richard Allan, Amit Antarkar, Santanu Chakraborty, Abhijit Deshmukh, Matthew A. Hummel, Ashish Jaiswal, Akhilesh Dixit, Ritesh Kakaria, Pankaj Patil, Russ Rackley, Andrew Shaw, Jeffrey P. Smith
-
Publication number: 20230127062Abstract: An auto-injector automatically dispenses a predetermined dose of medicament upon activation. The auto-injector includes a needle cover operative to engage an injection site and activate the injector. The needle cover is configured to move from a locked retracted position prior to a medicament dispensing operation to a locked extended position after the medicament dispensing operation. The non-removable needle cover prevents contact with the needle both before and after the medicament dispensing operation.Type: ApplicationFiled: December 16, 2022Publication date: April 27, 2023Applicant: Mylan Specialty L.P.Inventors: C. Michael Mesa, Dalita Rosemarie Tomellini, Mark Bumb Bremley, Sophie Rebecca Raven, Martin Joseph Murphy, Craig Malcolm Rochford, Stephen Philip Kirkwood
-
Publication number: 20230017559Abstract: An automatic injector dispenses a predetermined dose of medicament without a user having to manually force the needle into an injection site. The automatic injector includes a needle cover having a locked retracted position with respect to the injector housing prior to a medicament dispensing operation. The needle cover is operative to engage an injection site prior to a medicament dispensing operation.Type: ApplicationFiled: September 16, 2022Publication date: January 19, 2023Applicant: Mylan Specialty L.P.Inventors: Matthew Egerton Young, Sophie Rebecca Raven, Christopher John Hurlstone, Craig Malcolm Rochford, Colin James Mathews, John G. Wilmot, Robert L. Hill
-
Patent number: 11471614Abstract: An automatic injector dispenses a predetermined dose of medicament without a user having to manually force the needle into an injection site. The automatic injector includes a needle cover having a locked retracted position with respect to the injector housing prior to a medicament dispensing operation. The needle cover is operative to engage an injection site prior to a medicament dispensing operation.Type: GrantFiled: July 26, 2019Date of Patent: October 18, 2022Assignee: Mylan Specialty L.P.Inventors: Matthew Egerton Young, Sophie Rebecca Raven, Christopher John Hurlstone, Craig Malcolm Rochford, Colin James Mathews, John G. Wilmot, Robert L. Hill
-
Patent number: 9498437Abstract: The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.Type: GrantFiled: December 22, 2005Date of Patent: November 22, 2016Assignee: Mylan Specialty L.P.Inventor: Imtiaz Chaudry
-
Patent number: 9180126Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.Type: GrantFiled: February 8, 2012Date of Patent: November 10, 2015Assignee: Mylan Specialty L.P.Inventor: Imtiaz Chaudry
-
Patent number: 9138430Abstract: The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the active ingredient (e.g., paroxetine) in the large intestine of an individual in need thereof. In one embodiment, the present invention provides a controlled release paroxetine composition comprising paroxetine or a pharmaceutically acceptable salt thereof, in a controlled release swallow pharmaceutical formulation, that upon administration, releases the paroxetine substantially in the large intestine. For example, the controlled release paroxetine formulation may be formulated to release greater than about 50% of the paroxetine in the large intestine.Type: GrantFiled: December 27, 2007Date of Patent: September 22, 2015Assignee: Mylan Specialty L.P.Inventors: Jason Neely, David J. Wargo, Boyong Li, Thomas D. Reynolds
-
Publication number: 20140171398Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: ApplicationFiled: December 27, 2013Publication date: June 19, 2014Applicant: MYLAN SPECIALTY L.P.Inventors: Partha S. BANERJEE, Imtiaz A. CHAUDRY, Stephen PHAM
-
Patent number: 8663695Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.Type: GrantFiled: October 31, 2007Date of Patent: March 4, 2014Assignee: Mylan Specialty L.P.Inventor: Imtiaz Chaudry
-
Patent number: 8623851Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: November 24, 2009Date of Patent: January 7, 2014Assignee: Mylan Specialty L.P.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham